Literature DB >> 24512497

Nonalcoholic Fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance.

Soo-Kyung Kim1, Young Ju Choi, Byung Wook Huh, Seok Won Park, Eun Jig Lee, Yong-Wook Cho, Kap Bum Huh.   

Abstract

CONTEXT: The association between nonalcoholic fatty liver disease (NAFLD) and subclinical atherosclerosis in type 2 diabetes is controversial.
OBJECTIVE: The objective of the study was to investigate the participation of insulin resistance in the association of NAFLD and the carotid atherosclerotic burden in a large cohort of patients with type 2 diabetes. DESIGN, SETTING, AND PATIENTS: This was an observational study performed in 4437 consecutively enrolled patients with type 2 diabetes. MAIN OUTCOMES MEASURES: Hepatic steatosis and mean carotid intima-media thickness (C-IMT) were measured using ultrasonography. Insulin resistance was assessed using the short insulin tolerance test.
RESULTS: The prevalence of NAFLD was 72.7% in the whole study population. Among subjects with NAFLD, 23.2% were not insulin resistant. There were significant differences in C-IMT and the frequency of carotid atherosclerosis between groups classified by insulin resistance within the same NAFLD strata. C-IMT was highest in subjects with both NAFLD and insulin resistance [0.844 ± 0.004 (mean ± SE) mm vs 0.786 ± 0.008, 0.821 ± 0.007, and 0.807 ± 0.006 mm, P for trend <.001, respectively, in insulin sensitive subjects without NAFLD, insulin resistant subjects without NAFLD, and insulin sensitive subjects with NAFLD]. These differences remained after adjusting for potential confounders. However, C-IMT in subjects having only NAFLD or insulin resistance was not higher than that in those with neither NAFLD nor insulin resistance.
CONCLUSIONS: NAFLD is very common in subjects with type 2 diabetes, but NAFLD not accompanied by insulin resistance is not associated with a carotid atherosclerotic burden. However, having both NAFLD and insulin resistance seemed to be an independent predictor of increased C-IMT.

Entities:  

Mesh:

Year:  2014        PMID: 24512497     DOI: 10.1210/jc.2013-4133

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis.

Authors:  Michelle T Long; Emelia J Benjamin
Journal:  Circ Cardiovasc Imaging       Date:  2018-03       Impact factor: 7.792

Review 2.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

3.  Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes.

Authors:  Inkuk Lee; Hyeok-Hee Lee; Yongin Cho; Young Ju Choi; Byung Wook Huh; Byung-Wan Lee; Eun Seok Kang; Seok Won Park; Bong-Soo Cha; Eun Jig Lee; Yong-Ho Lee; Kap Bum Huh
Journal:  J Lipid Atheroscler       Date:  2020-01-13

Review 4.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.

Authors:  Ansel Shao Pin Tang; Kai En Chan; Jingxuan Quek; Jieling Xiao; Phoebe Tay; Margaret Teng; Keng Siang Lee; Snow Yunni Lin; May Zin Myint; Benjamin Tan; Vijay K Sharma; Darren Jun Hao Tan; Wen Hui Lim; Apichat Kaewdech; Daniel Huang; Nicholas Ws Chew; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah; Cheng Han Ng
Journal:  Clin Mol Hepatol       Date:  2022-03-02

6.  Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.

Authors:  Yong Ho Lee; Jae Hyeon Kim; So Ra Kim; Heung Yong Jin; Eun Jung Rhee; Young Min Cho; Byung Wan Lee
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

7.  Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.

Authors:  Manfredi Rizzo; Ali A Rizvi; Angelo Maria Patti; Dragana Nikolic; Rosaria Vincenza Giglio; Giuseppa Castellino; Giovanni Li Volti; Massimiliano Caprio; Giuseppe Montalto; Vincenzo Provenzano; Stefano Genovese; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2016-12-03       Impact factor: 9.951

8.  The Correlation and Risk Factors between Carotid Intima-Media Thickening and Alcoholic Liver Disease Coupled with Helicobacter pylori Infection.

Authors:  Qu Bao-Ge; Wang Hui; Jia Yi-Guo; Su Ji-Liang; Wang Zhong-Dong; Wang Ya-Fei; Han Xing-Hai; Liu Yuan-Xun; Pan Jin-Dun; Ren Guang-Ying
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

Review 9.  Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis.

Authors:  Xin Xu; Linlin Lu; Quanyong Dong; Xiaolin Li; Nannan Zhang; Yongning Xin; Shiying Xuan
Journal:  Lipids Health Dis       Date:  2015-12-03       Impact factor: 3.876

10.  Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes.

Authors:  Ryotaro Bouchi; Yujiro Nakano; Norihiko Ohara; Takato Takeuchi; Masanori Murakami; Masahiro Asakawa; Yuriko Sasahara; Mitsuyuki Numasawa; Isao Minami; Hajime Izumiyama; Koshi Hashimoto; Takanobu Yoshimoto; Yoshihiro Ogawa
Journal:  Cardiovasc Diabetol       Date:  2016-04-14       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.